Dmitry Balyasny’s AbbVie ABBV Stock Holding History

Dmitry Balyasny’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16M	Buy	8,600 +4,500	+110%	+$968K	﹤0.01%	1772
2026 Q1	$892K	Sell	4,100 -4,200	-51%	-$932K	﹤0.01%	2129
2025 Q4	$1.9M	Sell	8,300 -94,900	-92%	-$21.6M	﹤0.01%	1895
2025 Q3	$23.9M	Buy	103,200 +90,600	+719%	+$18.4M	0.03%	639
2025 Q2	$2.34M	Sell	12,600 -77,300	-86%	-$14.4M	﹤0.01%	1657
2025 Q1	$18.8M	Buy	89,900 +1,400	+2%	+$272K	0.03%	624
2024 Q4	$15.7M	Sell	88,500 -14,500	-14%	-$2.67M	0.02%	766
2024 Q3	$20.3M	Buy	103,000 +91,900	+828%	+$17.2M	0.03%	622
2024 Q2	$1.9M	Sell	11,100 -6,200	-36%	-$1.03M	﹤0.01%	1549
2024 Q1	$3.15M	Sell	17,300 -9,900	-36%	-$1.71M	0.01%	1390
2023 Q4	$4.22M	Buy	27,200 +7,500	+38%	+$1.09M	0.01%	1180
2023 Q3	$2.94M	Buy	+19,700	New	+$2.89M	0.01%	1272
2023 Q2	–	Sell	-59,500	Closed	-$9.48M	–	2214
2023 Q1	$9.48M	Hold	59,500	–	–	0.02%	798
2022 Q4	$9.62M	Hold	59,500	–	–	0.03%	765
2022 Q3	$7.99M	Buy	59,500 +44,500	+297%	+$6.39M	0.02%	788
2022 Q2	$2.3M	Buy	+15,000	New	+$2.29M	0.01%	1336
2021 Q3	–	Sell	-6,700	Closed	-$755K	–	1877
2021 Q2	$755K	Buy	+6,700	New	+$755K	﹤0.01%	1416
2020 Q2	–	Sell	-80,000	Closed	-$6.09M	–	1080
2020 Q1	$6.09M	Buy	+80,000	New	+$6.81M	0.07%	358
2017 Q4	–	Sell	-300,200	Closed	-$26.7M	–	2026
2017 Q3	$26.7M	Buy	+300,200	New	+$22.9M	0.1%	260
2016 Q1	–	Sell	-571,200	Closed	-$33.8M	–	1239
2015 Q4	$33.8M	Buy	+571,200	New	+$32.9M	0.23%	121
2015 Q3	–	Sell	-300,000	Closed	-$20.2M	–	1117
2015 Q2	$20.2M	Buy	300,000 +200,000	+200%	+$13.1M	0.12%	215
2015 Q1	$5.85M	Buy	+100,000	New	+$6.04M	0.05%	452

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dmitry Balyasny's ABBV Position: Q2 2026 in Review

Dmitry Balyasny increased its AbbVie (ABBV) stake by 1,673% in Q2 2026, buying an estimated $126M and bringing the position to 622,946 shares worth $157M. The position accounts for 0.2% of the portfolio, ranked #111.

Dmitry Balyasny first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $240M in Q2 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Dmitry Balyasny held 622,946 shares of AbbVie worth $157M as of Q2 2026.
Dmitry Balyasny bought 587,816 AbbVie shares in Q2 2026, an estimated $126M.
AbbVie made up 0.2% of Dmitry Balyasny's portfolio in Q2 2026, its #111 holding.
Dmitry Balyasny first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
Dmitry Balyasny's AbbVie position peaked at $240M in Q2 2025.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.